Skip to main content

Cullinan Therapeutics, Inc.

CGEM
Exchange
Nasdaq
Industry
Biological Products, (No Diagnostic Substances)
SEC CIK
0001789972

In the last 90 days, Cullinan Therapeutics, Inc. insiders filed 0 open-market purchases and 2 sales; 181 institutions reported holding it in 13F filings for Q3 2026, worth $1.08B in total; no superinvestor holds it.

Key figures

Market capClose on Nov 20, 2026
$577.1M
Insider buysOpen market, last 90 days
0
Insider sellsLast 90 days, $222.0K in total
2
13F holdersQ3 2026, +2 vs. previous quarter
181
13F valueReported value at the end of Q3 2026
$1.08B
Superinvestors holdingAt the end of Q3 2026
0

Price chart

From SEC filings, in USD.

Revenue, FY2025
–
No comparable prior period
Net income, FY2025
-$219.9M
No comparable prior period
Free cash flow, FY2025
-$175.8M
No comparable prior period
Revenue, Q3 FY2026
–
No comparable prior period

Short interest

See short data

From FINRA, settlement date Oct 30, 2026.

Short interest
7.93M
Shares sold short
Change
+288.7K
+3.8% vs. previous
Days to cover
13.33
At average daily volume

Superinvestors holding CGEM, Q3 2026

Go to the superinvestors tab

No superinvestor reported holding CGEM at the end of Q3 2026.

Latest insider trades

See all insider trades

Open-market purchases and sales by Cullinan Therapeutics, Inc. insiders from Form 4, newest first.

Insider trades
Filed (ET)Trade dateFiling delayInsiderTransactionSharesAvg priceValueHolding changeFlags
Nov 6, 2026 (view filing)5:00 PM ETNov 51 dayMichaelson JenniferChief Scientific OfficerSSale−4.00K$12.36−$49.4K−2.5%158.6K after10b5-1
Sep 10, 2026 (view filing)9:22 AM ETSep 82 daysMichaelson JenniferChief Scientific OfficerSSale−8.00K$21.57−$172.6K−4.8%158.8K after10b5-1
Aug 14, 2026 (view filing)5:00 PM ETAug 131 dayMichaelson JenniferChief Scientific OfficerSSale−30.0K$20.26−$607.8K−15.6%162.8K after10b5-1
Jul 7, 2026 (view filing)5:00 PM ETJul 61 dayMichaelson JenniferChief Scientific OfficerSSale−8.00K$17.82−$142.6K−4.7%162.8K after10b5-1
May 6, 2026 (view filing)May 51 dayMichaelson JenniferChief Scientific OfficerSSale−8.00K$14.62−$117.0K−4.6%166.8K after2 lots10b5-1
Mar 9, 2026 (view filing)Mar 54 daysMichaelson JenniferChief Scientific OfficerSSale−8.00K$15.68−$125.4K−4.5%170.8K after10b5-1
Feb 26, 2026 (view filing)Feb 251 dayMichaelson JenniferChief Scientific OfficerSSale−1.78K$14.14−$25.2K−1.0%174.8K after10b5-1
Feb 25, 2026 (view filing)Feb 23-242 daysMichaelson JenniferChief Scientific OfficerSSale−5.35K$14.31−$76.6K−2.9%176.6K after2 lots10b5-1
Feb 25, 2026 (view filing)Feb 241 dayAhmed NadimPresident and CEOSSale−13.5K$14.47−$195.6K−3.3%390.8K after
Feb 25, 2026 (view filing)Feb 241 dayJones Jeffrey AlanChief Medical OfficerSSale−4.58K$14.47−$66.3K−2.8%160.0K after

Top 10 13F holders, Q3 2026

See all 181 holders

The largest institutional positions in Cullinan Therapeutics, Inc. at the end of Q3 2026; share changes are against Q2 2026.

Institutions holding CGEM in Q3 2026
InstitutionSharesValue% of portfolioChange in sharesAction
MPM Oncology Impact Management LP9,721,081$149.2M11.49%−10,260−0.1%Reduced
Lynx1 Capital Management LP8,963,500$137.6M21.30%00.0%Unchanged
BVF Inc5,750,683$88.3M2.90%00.0%Unchanged
BlackRock, Inc.5,319,313$81.7M0.00%+86,547+1.7%Added
Price T Rowe Associates Inc4,091,640$62.8M0.01%+265,690+6.9%Added
Kynam Capital Management, LP3,114,132$47.8M2.65%00.0%Unchanged
Vanguard Capital Management LLC2,641,522$40.5M0.00%+27,456+1.1%Added
State Street Corp2,604,105$40.0M0.00%−1,064,522−29.0%Reduced
RTW Investments, LP2,364,347$36.3M0.37%00.0%Unchanged
Siren, L.L.C.1,793,410$27.5M0.65%−100,000−5.3%Reduced

Holders of 5% or more of CGEM

See all 4 holders and filings

Holders whose latest Schedule 13D or 13G filing reports 5% or more of Cullinan Therapeutics, Inc..

Largest holders of CGEM from 13D and 13G filings
HolderLatest formStakeChangeFirst filedLatest filingFiling
Biotechnology Value Fund L P13G/A9.99%6.49M shares0.00 ppfrom 9.99%Nov 8, 20219 filingsAug 14, 2026SEC
Lynx1 Capital Management LP13G/A9.80%5.77M shares−4.70 ppfrom 14.50%Aug 14, 20253 filingsNov 14, 2025SEC
Price T Rowe Associates Inc13G6.20%3.83M sharesNewAug 14, 20261 filingAug 14, 2026SEC
Kynam Capital Management, LP13G5.27%3.11M sharesNewMar 4, 20261 filingMar 4, 2026SEC